Bipolar spectrum in prostate cancer patients and its role in stress related symptoms. Issue 3 (18th January 2023)

• Record Type: Journal Article
• Authors: Chrobak, Adrian Andrzej; Przydacz, Mikołaj; Chłosta, Marcin; Machalska, Karolina; Turek, Aleksander; Popiół, Maja; Skalski, Michał; Arciszewska‐Leszczuk, Aleksandra; Chłosta, Piotr; Siwek, Marcin; Dudek, Dominika
• Is Part Of: Psycho-oncology. Volume 32:Issue 3(2023)
• Page Start: 438
• Page End: 445
• Publication Date: 2023-01-18
• Subjects: affective disorders -- bipolar disorder -- cancer -- comorbidity -- mood disorders -- oncology -- prostate cancer; Cancer -- Psychological aspects -- Periodicals; Cancer -- Social aspects -- Periodicals; Neoplasms -- psychology -- Periodicals; 616.9940019
• DOI: 10.1002/pon.6096
• Languages: English
• ISSNs: 1057-9249

Abstract

Abstract: Background: Studies show significant co‐occurrence of bipolar disorder and prostate cancer, as well as the presence of shared genes associated with both diseases. Our aim was to evaluate whether prostate cancer patients present bipolar spectrum symptoms and to establish their possible associations with stress related symptoms during diagnosis and the course of the cancer therapy. Methods: 200 participants were enrolled to this study: 100 prostate cancer patients and 100 healthy males. Bipolar spectrum symptoms were measured with the use of Mood Disorder Questionnaire and Hypomania Checklist‐32 (HCL‐32). Stress related symptoms were rated with The Impact of Events Scale‐Revised (IES‐R), Perceived Stress Scale‐10 (PSS‐10) and Generalised Self‐Efficacy Scale (GSES). Results: In comparison to healthy controls group, prostate cancer patients have shown higher HCL‐32 scores. Mood Disorder Questionnaire measures were associated with more severe stress related to prostate cancer diagnosis and treatment reflected by higher scores of IES‐R and its subscales (Avoidance, Intrusions and Hyperarousal). Mood Disorder Questionnaire, HCL‐32, PSS‐10, IES‐R and GSES measures were not associated with clinical characteristics of prostate cancer severity. Limitations: Cross‐sectional study model precluded identification of causal relationship among variables. Bipolar spectrum symptoms and stress related measures were based on auto‐questionnaires. Conclusions: To our best knowledge, this is the first study evaluating bipolar spectrum symptoms in prostate cancer patients. We have shown that this clinical group presents increased bipolarity traits compared to healthy individuals. Moreover, bipolar spectrum symptoms were associated with more severe stress related to the prostate cancer diagnosis and its treatment, reflected in avoidance, hyperarousal, and intrusions.